Skip to main content

Table 2 Details of efficacy calculations

From: Cost-effectiveness of different human papillomavirus vaccines in Singapore

    Source
  Bivalent
vaccine
Quadrivalent
vaccine
 
Reduction in the probability of HPV infection    
Assumed proportion of HPV 16/18 in cervical cancer, A 74.9% 74.9% [7]
Vaccine efficacy-percent reduction in HPV 16/18 persistent infections, B 95.0% 95.0% [23, 27, 28, 3240]
Assumed proportion of other high risk HPV in cervical cancer, C 23.4% 23.4% [7]
Vaccine efficacy-percent reduction in other high risk HPV persistent infections, D 68.4% 32.5% [3032]
Calculated reduction in the probability of HPV infection (AxB)+(CxD) 87.2% 78.8%  
Corection factor for CIN1    
Percent of HPV 1618 in CIN1 cases which are caused by oncogenic HPV, E 37.0%   
Correction factor for CIN1, A-E 37.9%   
Corection factor for CIN2/3    
Percent of HPV 1618 in CIN2/3 cases which are caused by oncogenic HPV, F 52.0%   
Correction factor for CIN2/3 A-F 22.9%